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Background: Smoking is a cause of cancer and polycythemia. Therefore, surgeons who treat patients with cancer
may also encounter patients with polycythemia. However, few cases of surgical patients with polycythemia have
been reported; in particular, a surgical case involving smokers’ polycythemia has never been reported. We herein
report a patient with lung cancer and smokers’ polycythemia who successfully underwent lobectomy with control
of hematocrit based on a modified formula in the perioperative period.
Case presentation: A 67-year-old man underwent abdominoperineal resection for rectal carcinoma in June 2008. A
ground glass opacity had been identified in the upper lobe of the right lung and was gradually enlarging. In March
2012, bronchoscopic cytology for investigation of the mass revealed non-small cell lung cancer, suggesting primary
lung non-small cell carcinoma (T1bN0M0, Stage IA). When he was referred to our hospital for surgery, his complete
blood count showed a red blood cell level of 6.50×106/μL, hemoglobin of 21.0 g/dL, and hematocrit of 60.1%. The
hematologists’ diagnosis was secondary polycythemia due to heavy smoking (smokers’ polycythemia) because the
white blood cell and platelet counts were within normal limits and the erythropoietin was not increased. We
calculated the appropriate phlebotomy and infusion volumes based on a formula that we modified. After 550 g of
blood was phlebotomized to reduce the hematocrit to approximately 55%, video-assisted right lung upper
lobectomy with lymph node dissection was performed in April 2012. The hematocrit was maintained at <50%
postoperatively, and the patient was uneventfully discharged on postoperative day 7. The predictive hematocrit and
measured hematocrit were very closely approximated in this case.
Conclusion: We experienced a patient with smokers’ polycythemia who underwent right upper lobectomy for
adenocarcinoma. The findings in this case report are meaningful for surgeons treating cancer patients because
there are few reports discussing the perioperative care of surgical patients with polycythemia.
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Smoking is a cause of cancer and polycythemia [1,2].
Therefore, surgeons who treat patients with cancer may
encounter cases of polycythemia. However, few surgical
patients with cancer and polycythemia have been
reported. We experienced a patient who underwent lung
lobectomy for lung cancer and had secondary polycy-
themia due to smoking. The most frequent complication
of polycythemia is thrombosis [3]. We managed this
patient’s hematocrit (HCT) to prevent thrombosis by
performing phlebotomy and infusion based on a formula* Correspondence: yasoos@hotmail.com
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reproduction in any medium, provided the orthat we modified. As a result, the predictive HCT and
measured HCT were very closely approximated, and we
succeeded in providing effective perioperative care. This
report provides useful information for the management
of surgical patients with polycythemia.
Case presentation
A 67-year-old man who underwent abdominoperineal
resection for rectal carcinoma in June 2008 was eva-
luated for an abnormal chest shadow appearing as a
ground glass opacity (GGO) in the right lung S1. It was
gradually enlarging, and histology by brush cytology via
bronchoscopy showed non-small cell lung cancer cells.
He presented to our hospital for surgical treatment of
the lung cancer (Figure 1).l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 Chest computed tomography and X-ray photography. (A) Computed tomography, June 2009. (B) Computed tomography, January
2011. (C) Computed tomography, March 2012. (D) Chest X-ray photography, March 2012. The GGO at the lateral aspect of right S1 was enlarging,
and it became a mass. GGO: ground glass opacity.
Table 1 Blood examination results on admission in March 2012
TP 7.5 g/dL WBC 8.2×103/μL PaCO2 39.8 mmHg
Alb 4.5 g/dL RBC 6.50×106/μL PaO2 95.0 mmHg
AST/ALT 24/18 IU/L Hb 21.0 g/dL HCO3
- 26.2 mmol/L
LDH 170 IU/L HCT 60.1% BE 1.9 mmol/L
T. Bil 1.4 mg/dL MCV 92.5 fl O2Hb 94.3%
ALP 367 IU/L MCH 32.3 pg COHb 2.3%
γ–GTP 102 IU/L MCHC 34.9 g/dL MetHb 0.5%
BUN/Cr 12.8/0.69 mg/dL Plt 216×103/μL SaO2 97.0%
UA 9.0 mg/dL Neut 65.3%
Na/Cl/K 143/104/4.2 mEq/L Lymph 15.6%
T–Cho 184 mg/dL Mono 14.2%
Eosino 4.0%





The blood gas was analyzed in room air. The reference value of erythropoietin is 8–36 mU/mL.
TP, total protein; Alb, albumin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactase dehydrogenase; T. Bil, total bilirubin; ALP, alkaline
phosphatase; γ–GTP, γ glutamyl transpeptidase; BUN, blood urea nitrogen; Cr, creatinine; UA, urinary acid; Na, sodium; Cl, chlorine; K, potassium; T–Cho, total
cholesterol; CEA, carcinoembryonic antigen; ProGRP, pro–gastrin–releasing peptide; CYFRA, cytokeratin fragment 19; CCr, creatinine clearance; WBC, white blood
cell; RBC, red blood cell; Hb, hemoglobin; HCT, hematocrit; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular
hemoglobin concentration; Plt, platelet; Neut, neutrophil; Lymph, lymphocyte; Mono, monocyte; Eosino, eosinophil; Baso, basophil; PaCO2, arterial CO2 tension;
PaO2, arterial O2 tension; HCO3
- , bicarbonate ion; BE, base excess; O2Hb, oxyhemoglobin; COHb, carboxyhemoglobin; MetHb, methemoglobin; SaO2, arterial
oxygen saturation.
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RBC (×106/μL ) 4.82 5.38 6.40 5.51 5.77 6.28 6.39
Hb (g/dL) 15.3 18.1 20.5 18.2 19.5 20.6 21.1
HCT (%) 44.0 50.2 58.2 52.7 54.3 57.2 60.8
































Figure 3 Predictive HCT and phlebotomy in the perioperative
period. HCT: hematocrit.
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http://www.biomedcentral.com/1756-0500/6/38His hypertension was being treated with 5 mg of amlo-
dipine a day. He had been a three-packs-a-day smoker for
40 years, and he stopped smoking 4 weeks before surgery.
The blood examination on admission in March 2012
suggested polycythemia based on a red blood cell (RBC)
count of 6.50×106/μL, hemoglobin (Hb) of 21.0 g/dL, and
HCT of 60.1%. Other blood cells and erythropoietin were
not increased (Table 1). His complete blood count had
been almost within normal limits until June 2009. Since
September 2009, the RBC count, Hb, and HCT had been
increasing (Table 2). The size of the GGO and its solid
component had also been enlarging. The respiratory func-
tion examination showed obstructive impairment based
on a vital capacity (VC) of 5.19 L, %VC of 151.3%, 1 se-
cond forced expiratory volume (FEV1.0) of 3.14 L,
FEV1.0% of 63.7%, %FEV1.0 of 60.5% and diffusing
capacity of the lung for carbon monoxide (DLCO) of
3.26 mL/min/mmHg/L.
Although a bone marrow examination was not per-
formed, only one factor in the major and minor diagnostic
criteria for polycythemia vera (PV) did not match [4,5]. In
the major criteria, HCT was >60%, the cause of the sec-
ondary erythrocytosis was smoking, and splenomegaly was
not present. In the minor criteria, the platelet count was
<400×103/μL, the neutrophil count was <12.5×106/μL,
and the serum erythropoietin level was within normal li-
mits. Consultation with hematologists led us to conclude
that these data were contradictive to a myeloproliferative
disorder (e.g., chronic myeloid leukemia, polycythemia
rubra vera, or essential thrombocythemia), and the diag-
nosis was smokers’ polycythemia (SP).Figure 2 Formula for predictive HCT after phlebotomy. HCT: hematocr
weight of phlebotomy, SG: specific gravity, Vi: volume of infusion.We calculated the appropriate phlebotomy and
infusion volumes based on a formula that we modified
(Figure 2). A total of 350 and 200 g was phlebotomized
1 week and 4 days before the operation, respectively, to re-
duce the HCT to approximately 55%. Video-assisted right
lung upper lobectomy and lymph node dissection were
then performed in April 2012. The total intraoperative in-
fusion volume was 2350 mL (7.8 mL/kg/hr), intraoperative
urinary output was 500 mL, and intraoperative blood loss
was 110 g (Figure 3). We maintained the HCT at <50%,
and the patient was uneventfully discharged on postopera-
tive day 7.it, HCT': predictive HCT after phlebotomy, BW: body weight, Wp:
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carcinoma component occupied >90%. Immunohistologic
staining for erythropoietin was negative. The pathological
diagnosis was primary lung adenocarcinoma, 42×40×26
mm, pT2aN0M0 Stage IB (lymph node station 2, 0/1; 7,
0/4; 10, 0/7).
The serum erythropoietin level 1 month after
discharge was normal at 11.2 mU/dL, as before the
operation. However, the Hb and HCT in November
2012 were 22.0 g/dL and 61.0%, respectively.
Conclusion
Smoking is one of the most notorious carcinogenic risk fac-
tors and a recognized cause of lung cancer [1]. Smoking is
also a known cause of SP [2]. SP with hypertension is called
Gaisböck syndrome and is frequently associated with cere-
brovascular disease [6]. However, there are very few reports
on surgery for patients with SP. Therefore, we reviewed the
complications and treatments of PV [5,7-10]. According to
the Polycythemia Vera Study Group, the most common
cause of death in patients with polycythemia is thrombosis
[3,10]. Thus, we formulated countermeasures to prevent
the thrombosis during the perioperative period.
Cerebrovascular disease and high HCT in patients with
SP are correlated, and treatments to prevent these compli-
cations include anticoagulants and/or antiplatelet agents
and cytoreduction [3,11,12]. Thus, we chose to reduce the
HCT before the operation because we had to be wary of
using anticoagulants or antiplatelets during the periopera-
tive period [13]. The optimal HCT is unclear in patients
with SP, even in patients with PV [14], because, on theo-
retical grounds, erythrocytosis in this situation represents
to a certain extent an “appropriate” physiological response
to hypoxemia [15]. Thus, whatever the ideal HCT in cases
of primary polycythemia, the corresponding ideal in cases
of SP is likely to be higher [15]. We decided that the target
HCT just before surgery was 55%, considering the average
amount of intraoperative blood loss and for lobectomy in
our hospital.
The total circulating blood volume is almost 1/13 (7.5%)
of body weight, the RBC mass is 24 to 30 mL/kg, and the
plasma volume is 39 to 49 mL/kg [16]. Approximately
25% of physiological saline remains in the vascular space,
and the remaining 75% is distributed throughout the inter-
stitial tissue [17]. We calculated the phlebotomy volume
using the modified formula in Figure 2 [18]. Determi-
nation of the predictive HCT and measured HCT in the
perioperative period is shown in Figure 3.
The most important condition in this case was that
homeostasis was maintained because of the presence of
normal renal function and the fact that the patient under-
went elective surgery. There are many methods and
approaches to accurate calculation of the total circulating
blood volume. However, this formula would be reliable ifwe had assumed that the body fluid, excluding the phle-
botomy and infusion volumes, was in a stationary state.
Practically, the predictive HCT and measured HCT were
very closely approximated in this case.
It is unknown why the polycythemia became obvious
after June 2008 and erythrocytosis developed 8 months
after surgery. However, Weinberg et al. reported that sig-
nificant increases in the prevalence and frequency of mu-
tation of the Janus kinase 2 (JAK2) gene, the protein of
which is especially important for controlling the produc-
tion of blood cells from hematopoietic stem cells, may be
related to poor DNA repair in smokers as a result of the
increased demand for erythrocyte production [19]. JAK2
mutation may have been present in this patient.
In conclusion, we experienced a patient with SP who
underwent right upper lobectomy for adenocarcinoma.
Smoking is a cause of cancer and polycythemia. Thus, this
is a salutary case report for surgeons treating cancer
patients because there are few reports discussing the pe-
rioperative care of surgical patients with polycythemia.
This report is based on the experience of only one patient.
Therefore, experience with surgical patients with SP
should be accumulated and shared among surgeons to
understand and improve treatment these cases.
Consent
Written informed consent for the perioperative care and
operation in this case was obtained on admission in ac-
cordance with institutional guidance based on the Helsinki
Declaration. At the time of discharge, we reconfirmed that
the patient gave permission to publish a case report about
his clinical course. A copy of the written consent is avail-
able for review by the Editor-in-Chief of the journal.
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